Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
This is a randomized, controlled, open-label, phase III study to explore the efficacy and safety of Apatinib in combination with standard first-line endocrine therapy for the HR+/ HER2-SNF4 subtype of advanced breast cancer. The study was used to explore the efficacy of Apatinib in combination with standard endocrine therapy.
Advanced Breast Cancer|HR+/HER2- Breast Cancer
DRUG: Apatinib|DRUG: CDK4/6 Inhibitor|DRUG: Aromatase inhibitor and Fulvestrant
Progression Free Survival (PFS), The interval from randomization until the first occurrence of disease progression (according to RECIST 1.1) or death from any cause, which ever occurs first., Approximately 5 years
Clinical Benefit Rate (CBR), CBR is the total percentage of participants who achieved a complete response, partial response, or had stable disease for 6 months or more., Approximately 5 years|Objective Response Rate (ORR), ORR is defined as the proportion of participants who have a complete response (CR) or partial response (PR) based on BICR and investigator assessment using RECIST 1.1., Approximately 5 years|Overall Survival (OS), OS is defined as the time from randomisation until the date of death due to any cause., Approximately 5 years|Safety and tolerability, Number of adverse events according to NCI-CTCAE Version 5.0 per each treatment arm., Approximately 5 years
This is a randomized, controlled, open-label, phase III study to explore the efficacy and safety of Apatinib in combination with standard first-line endocrine therapy for the HR+/ HER2-SNF4 subtype of advanced breast cancer. The study was used to explore the efficacy of Apatinib in combination with standard endocrine therapy.